Ahnert, J. R., Rothe, M., Mangat, P. K., Garrett-Mayer, E., Cannon, T. L., Hobbs, E., … Schilsky, R. L. (2024). Afatinib in patients (pts) with solid tumors with neuregulin 1 (NRG1) fusions: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 42).

Ahnert, Jordi Rodon, Michael Rothe, Pam K. Mangat, Elizabeth Garrett-Mayer, Timothy Lewis Cannon, Evthokia Hobbs, Gregory Peter Kalemkerian, et al. “Afatinib in patients (pts) with solid tumors with neuregulin 1 (NRG1) fusions: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 42, 2024.

Ahnert JR, Rothe M, Mangat PK, Garrett-Mayer E, Cannon TL, Hobbs E, et al. Afatinib in patients (pts) with solid tumors with neuregulin 1 (NRG1) fusions: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. In: JOURNAL OF CLINICAL ONCOLOGY. 2024.

Ahnert, Jordi Rodon, et al. “Afatinib in patients (pts) with solid tumors with neuregulin 1 (NRG1) fusions: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.” JOURNAL OF CLINICAL ONCOLOGY, vol. 42, no. 16, 2024.

Ahnert JR, Rothe M, Mangat PK, Garrett-Mayer E, Cannon TL, Hobbs E, Kalemkerian GP, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Afatinib in patients (pts) with solid tumors with neuregulin 1 (NRG1) fusions: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. JOURNAL OF CLINICAL ONCOLOGY. 2024.